LOTTE BIOLOGICS

Learn about the business status and future vision of our Syracuse Bio Campus from Ryan Stelick, the Manufacturing Director at our Syracuse Bio Campus. https://lnkd.in/gFdgj2rA With over 15 years of experience, Ryan is a long-term employee of the Syracuse Bio Campus and a key member of LOTTE BIOLOGICS, exemplifying our team’s expertise and commitment to excellence. Over 460 staff members with an average tenure exceeding 10 years are currently employed at our Syracuse Bio Campus, highlighting our specialized and experienced workforce dedicated to biomanufacturing. The facility has achieved over 62 production approvals from Health Authorities worldwide including the FDA, EMA, and PMDA. Leveraging more than 18 years of Drug Substance manufacturing expertise at the Syracuse Bio Campus, LOTTE BIOLOGICS plans to offer optimized ADC Conjugation services tailored to our clients' needs. The ongoing expansion of our ADC production facility is expected to be completed by Q4 2024, with GMP approval targeted for Q1 2025. Please visit the links below to learn more about our services at the Syracuse Bio Campus. ➡️ Syracuse Bio Campus: https://lnkd.in/gxDEH-iG ➡️ ADC Conjugation Service: https://lnkd.in/gJGEpXmz ➡️ For inquiries: https://lnkd.in/dfCuEFa7 (Please leave a message through the 'Contact us' button)

We would like to sincerely thank everyone who joined us in celebrating the groundbreaking ceremony of LOTTE BIOLOGICS’ Songdo Bio Campus! Your presence and support made the day truly special. 📹 Highlight Reel: Relive the memorable moments of the day with highlights from the event. Watch the video below to experience the excitement of this significant milestone. 

We are proud to announce that LOTTE BIOLOGICS held the Ground Breaking Ceremony for Plant 1 of our Incheon Songdo Bio Campus on July 3rd. Hosted by LOTTE Group Chairman Dong-Bin Shin and LOTTE BIOLOGICS CEO Richard Lee, we are grateful to all who attended this landmark occasion for our company. LOTTE BIOLOGICS plans to build three Bio Plants in the Songdo IFEZ bio cluster by 2030, with a total antibody pharmaceutical production capacity of 360kL. Through our new Songdo Bio Plant and our Syracuse Bio Plant in New York, LOTTE BIOLOGICS is committed to delivering excellence and is dedicated to improving the lives of patients worldwide as a leading global CDMO. 

We are pleased to announce that LOTTE BIOLOGICS had a successful BIO International 2024 event. Thanks to your strong interest and support, we had the opportunity to engage with approximately 1,500 attendees at our booth.   Your queries and the business meetings we held were crucial in driving our business forward. We remain committed to delivering innovative CDMO services in the biotech industry and growing alongside you.   A heartfelt thank you to everyone who stopped by our booth. We look forward to continuing this exciting journey together.   For more information about LOTTE BIOLOGICS, please visit our website : https://lnkd.in/gKxmCvgS See you at BIO International 2025 in Boston!   #LOTTEBIOLOGICS #BIOInternational2024 #BIO2024 #Biotech #Innovation

Today marks the second anniversary of LOTTE BIOLOGICS, a significant milestone in our journey.🎉 We extend our heartfelt gratitude to our dedicated team and esteemed partners for their unwavering support and commitment. Your contributions have been instrumental in our growth and success. As we celebrate this special occasion, we look forward to many years of outstanding achievements. Together, we will continue to push boundaries, setting new standards of excellence in the biopharmaceutical industry. Here's to a future filled with success, collaboration, and transformative manufacturing innovation. #LOTTEBIOLOGICS #HAPPYANNIVERSARY

Looking for a CDMO partner with end to end solutions? Visit LOTTE BIOLOGICS at #BIO2024! If you’re interested in learning about our capabilities in antibody drug production and our plans to offer #ADC services, visit us at Booth #5121. Our team is ready to connect with you!

LOTTE BIOLOGICS is excited to announce our participation in the BIO International Convention 2024! You can find us at Booth No. 5121, where we will be engaging with a wide range of potential clients to showcase the unique strengths and synergistic capabilities of our Syracuse Bio Campus and Songdo Bio Campus. With these two state-of-the-art facilities, LOTTE BIOLOGICS is well-equipped to meet the diverse needs of our clients, from large-scale antibody drug production to ADC manufacturing. If you're looking to propel your business to success, visit us at Booth No. 5121. Partner with us, and together we will elevate your business to new heights. #LOTTEBIOLOGICS #BIOUSA2024 #BIOInternationalConvention

We are proud to share that Richard Lee, CEO of LOTTE BIOLOGICS, had the honor of speaking at the (AAPBS) Association of Asia-Pacific Business Schools' Academic Conference. Before engaging in a discussion on "Innovations in K Technology", Mr. Lee presented a short talk about the Korean Biopharma Landscape 🔬 Speaking on Key Points (such as):  - Addressing Health Inequality  - Balancing Innovation and Capacity  - Korea's Strategic Advantage Mr. Lee fielded questions from the audience on a range of topics, ranging from R&D partnerships to open innovation. We are grateful for the opportunity to contribute to such a meaningful dialogue and look forward to continuing our efforts in driving biopharma advancements. #AAPBS #academicconference2024 #YonseiUniversity

LOTTE BIOLOGICS has signed an LOI (Letter of Intent) with Merck Process Solutions to enhance their manufacturing and process development of biopharmaceuticals. Through this agreement, LOTTE BIOLOGICS will receive essential raw materials and solutions from Merck for pharmaceutical development and manufacturing within the Songdo Bio Campus. This collaboration will provide sophisticated manufacturing processes and will significantly boost our technological competitiveness. We look forward to a fruitful collaboration between our two companies in the future. Stay tuned for more updates on this exciting collaboration.

Join LOTTE BIOLOGICS at BIO International, June 3-6 in San Diego. As a committed CDMO company, we specialize in the manufacture of monoclonal antibodies, bispecific antibodies, fusion proteins, and ADCs for both clinical & commercial supply. We would like to invite you to schedule a meeting to explore how we can support your assets through our capabilities. Schedule a meeting via BIO One-to-One Partnering or request a meeting directly through the link below: - Link for direct meeting request: https://lnkd.in/g4MbqGrF - LOTTE BIOLOGICS Partnering page: https://lnkd.in/g_4Bm2WJ